Lincoln Pharmaceuticals Ltd is Rated Sell

Current Rating and Its Significance

MarketsMOJO assigns Lincoln Pharmaceuticals Ltd a 'Sell' rating, indicating a cautious stance for investors considering this stock. This rating suggests that the stock is expected to underperform relative to the broader market or its sector peers in the near to medium term. Investors are advised to carefully evaluate the risks before committing capital, as the current outlook points to challenges in growth and valuation.

Here's How Lincoln Pharmaceuticals Ltd Looks Today

As of 01 January 2026, Lincoln Pharmaceuticals Ltd exhibits a Mojo Score of 37.0, which places it firmly in the 'Sell' category. This score reflects a moderate improvement from the previous 'Strong Sell' grade, which was adjusted on 07 August 2025 when the Mojo Score rose from 28 to 37. Despite this improvement, the overall outlook remains cautious.

Quality Assessment

The company's quality grade is assessed as average. Over the past five years, Lincoln Pharmaceuticals has demonstrated modest growth, with net sales increasing at an annual rate of 9.21% and operating profit growing at 5.37%. While these figures indicate some expansion, they fall short of the robust growth rates typically favoured by investors seeking strong quality stocks. Additionally, recent quarterly results show a decline in profitability, with profit after tax (PAT) falling by 24.1% to ₹19.98 crores and profit before tax (PBT) excluding other income decreasing by 12.98% to ₹21.58 crores. The return on capital employed (ROCE) stands at a relatively low 15.46%, signalling limited efficiency in generating returns from capital invested.

Valuation Perspective

From a valuation standpoint, Lincoln Pharmaceuticals is considered attractive. The stock trades at levels that may appeal to value-oriented investors, especially given its microcap status. However, the attractive valuation is tempered by the company's subdued growth prospects and recent financial performance. The lack of significant institutional interest, particularly from domestic mutual funds which currently hold 0% stake, further suggests that the market remains cautious about the stock's potential at prevailing prices.

Financial Trend

The financial trend for Lincoln Pharmaceuticals is currently flat. The company’s recent quarterly results indicate stagnation or decline in key profitability metrics. The subdued growth in net sales and operating profit over the last five years, combined with the recent quarterly contraction in PAT and PBT, highlight challenges in maintaining momentum. This flat trend is a concern for investors looking for companies with accelerating earnings and cash flow generation.

Technical Analysis

Technically, the stock is rated bearish. Price performance over various time frames reflects this negative momentum. As of 01 January 2026, Lincoln Pharmaceuticals has delivered a 1-year return of -43.36%, underperforming the BSE500 index over the last three years, one year, and three months. The stock’s short-term performance is also weak, with a 1-month decline of 5.43% and a 6-month drop of 14.85%. This bearish technical outlook suggests that the stock may continue to face downward pressure unless there is a significant change in fundamentals or market sentiment.

Investor Considerations

For investors, the 'Sell' rating on Lincoln Pharmaceuticals Ltd signals caution. While the valuation appears attractive, the combination of average quality, flat financial trends, and bearish technicals suggests that the stock may not offer favourable risk-reward dynamics at present. The absence of domestic mutual fund participation further underscores the market’s hesitancy. Investors should weigh these factors carefully and consider alternative opportunities within the Pharmaceuticals & Biotechnology sector that demonstrate stronger growth and technical momentum.

Summary

In summary, Lincoln Pharmaceuticals Ltd’s current 'Sell' rating reflects a balanced assessment of its average quality, attractive valuation, flat financial trend, and bearish technical outlook. The stock’s recent performance and fundamental indicators suggest limited upside potential in the near term. Investors should approach this stock with caution and consider the broader market context and sector alternatives before making investment decisions.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →